Sugi Predict

Sugi Predict / Compounds / SCHEMBL1683406

SCHEMBL1683406

SCHEMBL1683406

COc1cnc2c(c1)cc(C)n2S(=O)(=O)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 4/20 0.46
▸ POLB P06746 2/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ SLC40A1 Q9NP59 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.41
▸ CXCL8 P10145 1/20 0.41
▸ NOD1 Q9Y239 1/20 0.41
▸ MAPT P10636 4/20 0.41
▸ TSHR P16473 3/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ HPGD P15428 2/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ PKM P14618 1/20 0.40
▸ PTGDR2 Q9Y5Y4 1/20 0.39
▸ LMNA P02545 2/20 0.39
▸ HTT P42858 2/20 0.39
▸ BRD4 O60885 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1683455 0.90 KDM4E (0.44) HTR6L3MBTL1MEN1KMT2AKDM4E
SCHEMBL22494274 0.87 HTR6 (0.44) HTR6POLBL3MBTL1MEN1KMT2A
SCHEMBL23916331 0.85 NPC1 (0.46) HTR6L3MBTL1MEN1KMT2AKDM4E
SCHEMBL1683456 0.85 KEAP1 (0.39) HTR6POLBL3MBTL1MEN1KMT2A
SCHEMBL1773113 0.81 CXCL8 (0.43) HTR6MEN1KMT2ASLC40A1KDM4E
SCHEMBL7515939 0.81 ENPP3 (0.50) HTR6SLC40A1KDM4ECXCL8NOD1
SCHEMBL1683418 0.79 HTR6 (0.62) HTR6POLBL3MBTL1MEN1KMT2A
SCHEMBL5716762 0.79 HDAC3 (0.57) HTR6POLBL3MBTL1MAPTRAB9A
SCHEMBL5716675 0.79 HDAC3 (0.43) HTR6POLBL3MBTL1MEN1KMT2A
SCHEMBL5716689 0.77 TUBB4A (0.51) MEN1KMT2AMAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022140527-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2022-06-30 — — WO disclosed
EP-1539763-B1 AZAINDOLE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2011-04-13 — — EP disclosed
EP-1309587-B1 CINNOLINE COMPOUNDS ASTRAZENECA AB (SE) 2008-12-31 — — EP disclosed
EP-1309587-B1 CINNOLINE COMPOUNDS ASTRAZENECA AB (SE) 2008-12-31 — — EP disclosed
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity HENNEQUIN LAURENT FRANCOIS ANDRE 2008-12-18 — — US disclosed
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity HENNEQUIN LAURENT FRANCOIS ANDRE 2008-12-18 — — US disclosed
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity HENNEQUIN LAURENT FRANCOIS ANDRE 2008-12-18 — — US disclosed
US-7371765-B2 Quinoline derivatives having VEGF inhibiting activity ASTRAZENECA AB (SE) 2008-05-13 — — US disclosed
EP-1539763-A4 AZAINDOLE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2007-08-01 — — EP disclosed
US-20060148819-A1 Chemical compounds HENNEQUIN LAURENT F A 2006-07-06 — — US disclosed
US-20040063707-A1 Azaindole kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-04-01 — — US disclosed
WO-2004009601-A1 AZAINDOLE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-29 — — WO disclosed
US-20030212055-A1 Cinnoline compounds ASTRAZENECA AB (SE) 2003-11-13 — — US disclosed
US-20030207878-A1 Chemical compounds ASTRAZENECA AB (SE) 2003-11-06 — — US disclosed
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity ASTRAZENECA AB (SE) 2003-10-23 — — US disclosed
EP-1313726-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY AstraZeneca AB (SE) 2003-05-28 — — EP disclosed
EP-1309587-A1 CINNOLINE COMPOUNDS AstraZeneca AB (SE) 2003-05-14 — — EP disclosed
WO-2002016348-A1 ANTIANGIOGENIC BICYCLIC DERIVATIVES ASTRAZENECA AB (SE) 2002-02-28 — — WO disclosed
WO-2002012228-A1 CINNOLINE COMPOUNDS ASTRAZENECA AB (SE) 2002-02-14 — — WO disclosed
WO-2002012226-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity VEGFA, FLT1, FLT4 HTR6 4168/4885POLB 1378/4885L3MBTL1 4322/4885
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity VEGFA, FLT1, FLT4 HTR6 2996/4885POLB 1225/4885L3MBTL1 3797/4885
US-20040063707-A1 Azaindole kinase inhibitors FGFR1, FGFR2, FLT1 HTR6 2351/4885POLB 4024/4885L3MBTL1 4671/4885
US-20060148819-A1 Chemical compounds VEGFA, NOS3, FLT4 HTR6 1847/4885POLB 3440/4885L3MBTL1 4217/4885
US-20030207878-A1 Chemical compounds CYP3A7, HTR3C, CNR1 HTR6 997/4885POLB 2617/4885L3MBTL1 4318/4885
US-20030212055-A1 Cinnoline compounds VEGFA, PGF, CCR7 HTR6 2075/4885POLB 2997/4885L3MBTL1 4225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.